Results 221 to 230 of about 9,740,987 (348)

Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis

open access: yesArthritis &Rheumatology, Accepted Article.
Background Transition from long‐term denosumab to PTH‐analogs or romosozumab might expose patients to the risk of the so‐called rebound phenomenon. Adding romosozumab to denosumab might represent an option in patients experiencing a fracture while on denosumab.
Giovanni Adami   +10 more
wiley   +1 more source

Nationwide temporal trends in adverse pregnancy outcomes and treatments in systemic lupus erythematosus pregnancy over two decades in Sweden

open access: yesArthritis &Rheumatology, Accepted Article.
Objective This nationwide descriptive study examined temporal trends in adverse pregnancy outcomes (APOs) and treatments in systemic lupus erythematosus (SLE) pregnancies in Sweden over 2003‐2022. Methods Using nationwide Swedish registers, we identified 1,417 pregnancies of women with prevalent SLE and delivery dates in 2003‐2022, and matched them to ...
Ngoc V. Nguyen   +6 more
wiley   +1 more source

Plasma Proteomics Identifies TAOK3 as a Potential Biomarker of Rheumatoid Arthritis Activity and a Novel Therapeutic Target

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Bone destruction associated with active rheumatoid arthritis (RA) remains a major therapeutic challenge, with a lack of reliable molecular markers reflecting bone injury. This study aims to identify novel biomarkers linked to bone destruction in active RA through proteomic analysis, providing new strategies for precise monitoring and targeted
Pengfei Xin   +15 more
wiley   +1 more source

Risk factors for relapse in ANCA‐associated vasculitis among patients with relapse after induction of remission with rituximab

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To determine risk factors for relapse of ANCA‐associated vasculitis (AAV) after re‐induction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post‐hoc analysis of the RITAZAREM clinical trial. Patients 15 years or older with AAV and a positive test for anti‐proteinase‐3 (PR3‐) or anti‐myeloperoxidase ...
Ellen Romich   +10 more
wiley   +1 more source

Immune responses in the microenvironment after spinal-cord injury: A bibliometric study from 2005 to 2024. [PDF]

open access: yesMedicine (Baltimore)
Zhou Y   +7 more
europepmc   +1 more source

Mapping the Research Trends by Co-word Analysis Based on Keywords from Funded Project

open access: yes, 2016
Xiuwen Chen   +4 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy